As per the agreement, Zenobia will continue to use its capabilities in fragment-based lead discovery (FBLD) to advance its internal LRRK2 drug discovery program independently of Lundbeck.
Under the agreement, Zenobia will complete x-ray crystal structures of wild-type and the Parkinson’s disease-associated mutant, G2019S, in complex with Lundbeck lead compounds.
Zenobia retains all rights and ownership of the LRRK2 structure and to their internal LRRK2 chemistry program.
Zenobia founder, president and CSO Vicki Nienaber said that they are pleased that their expertise in protein expression, purification and crystallization has been recognized by Lundbeck.